NewLimit is a Biotech company based in San Francisco, CA. It has raised $682M in total funding. Latest round: Series C.
NewLimit funding overview
NewLimit is a Biotech company based in San Francisco, CA. NewLimit has raised $682M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in June 2026. The round record for NewLimit runs through 2026; nothing later has been disclosed. Investors on record include Founders Fund, Kleiner Perkins, Eli Lilly, Greenoaks, Thrive Capital, Valor Equity Partners and 17 others. 23 distinct backers are named across the disclosed rounds.
NewLimit at a glance
Total raised
$682M
Latest round
Series C
Latest round date
June 2026
Industry
Biotech
Headquarters
San Francisco, CA
Notable investors
Founders Fund, Kleiner Perkins, Eli Lilly, Greenoaks, Thrive Capital, Valor Equity Partners, Nat Friedman, Daniel Gross
Frequently asked about NewLimit funding
How much has NewLimit raised?
NewLimit has raised $682M in total disclosed funding across the rounds on record.
Who has invested in NewLimit?
Founders Fund, Kleiner Perkins, Eli Lilly, Greenoaks, Thrive Capital, Valor Equity Partners are named among the investors backing NewLimit.
What was the latest NewLimit funding round?
The most recent disclosed round is a Series C, announced in June 2026.
Where is NewLimit based?
NewLimit is based in San Francisco, CA.
What sector does NewLimit operate in?
NewLimit is tracked under Biotech from San Francisco, CA, with $682M in disclosed funding.
When did NewLimit last raise?
The last disclosed NewLimit round closed in June 2026 at Series C.
We update the NewLimit record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in San Francisco and their backers are listed below.
